Huateng Pharmaceutical, a global supplier of pharmaceutical intermediates, offers Favipiravir intermediates 6-Bromo-3-hydroxypyrazine-2-carboxamide (CAS NO. 259793-88-9) for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation

Favipiravir, also known as T-705 or Avigan, is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus) disease.